Diabetes mellitus (DM) is a widespread metabolic disorder with profound effects on vital organs. Often referred to as a “systemic” or “multi-organ” disorder due to the impact on key organs, such as the kidneys, pancreas, eyes, and heart, DM is characterized by elevated blood glucose levels due to insufficient insulin production. DM consists of three subtypes (type 1 DM, type 2 DM, and gestational
... [Show full abstract] DM). Approximately 537 million adults are living with DM, a number predicted to increase to 643 million by 2030, according to the International Diabetes Federation (IDF) data. With the rising prevalence of DM, the Pan American Health Organization and World Health Organization estimate an age-standardized mortality rate of 20.9 deaths per 100,000 people. Therefore, it is important to study the prevention and cure of DM and determine the underlying mechanism and regulation. Numerous receptors and pathways help to regulate DM. This article delves into the intricate regulatory mechanisms underlying DM involving receptors and pathways, such as K ATP (sulfonylurea), 5′AMP-activated protein kinase enzyme (biguanides), PPAR gamma, alpha-glucosidase, Glucose transporters (GLUT4), dipeptide peptidase-4 (DPP-4), and sodium-glucose co-transporters type 2 (SGLT2). The article highlights recent advances from 2020–2024 in synthesizing compounds targeting specific receptors for diabetes management. In so doing, insights into newly synthesized compounds, marketed drugs, phytoconstituents, and drugs currently in clinical trials will be provided. The role of each receptor in maintaining glucose homeostasis is reviewed in detail and various compounds with potential as effective antidiabetic agents are evaluated. This comprehensive review presents the pharmacologic mechanisms underlying these receptors and an in-depth analysis of promising new drug candidates.